HW



### ATTORNEY DOCKET NO. 13099.0023U2 APPLICATION NO. 10/827,111

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
TACHDJIAN et al.	)	Confirmation No.: 1476
Application No.: 10/827,111	)	Group Art Unit: 1614
Filed: April 19, 2004	)	Examiner: Unassigned
FOR: "SUBSTITUTED DIHYDRONAPHTHALENE AND ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,	)	
CANCER AND OTHER DISEASES"	)	

### INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 NEEDLE & ROSENBERG, P.C. Customer Number 23859

October 29, 2004

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

232308\_8 DOC 1

In accordance with the provisions of M.P.E.P. § 2001.06(b) and 37 C.F.R. § 1.98(b)(3), Applicants would like to bring to the attention of the Examiner the existence of the co-pending unpublished patent application(s) identified below, which were filed in the United States Patent and Trademark Office:

	Application No.	<b>Date Filed</b>	<u>Inventors</u>	Attorney Docket No.
1.	09/655,460	09/05/2000	Pfahl et al.	13099.0013U3
2.	10/894,411	07/19/2004	Pfahl et al.	13099.0013U5
3.	10/094,142	03/07/2002	Pfahl et al.	13099.0014U2
4.	10/769,725	01/29/2004	Pfahl et al.	13099.0022U2

In accordance with the requirements of 37 C.F.R. § 1.98(a)(2)(iii), a copy of the above-referenced application specification(s), including the claims and drawings thereof, is enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

2

232308\_8.DOC

ŧ

#### ATTORNEY DOCKET NO. 13099.0023U2 APPLICATION NO. 10/827,111

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mark A. Murphy, Ph.D. Registration No. 42,915

NEEDLE & ROSENBERG, P.C. Customer Number 23859 (678) 420-9300 Phone (678) 420-9301 Fax

CERTIFICATE OF MAILING UNDER 37 C.F.R. §	<b>§</b> 1	1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in two (2) boxes addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Mark A. Murphy, Ph.D.

Date

		5	•
	Com	plete if Known	
	Application Number	10/827,111	
	Filing Date	04/19/2004	
	First Named Inventor	TACHDJIAN et al.	
	Group Art Unit	1614	
	Examiner Name	Unassigned	

MAUE			U.S. PATE	NT DOCUMENTS	·		
Examiner Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	Al	US-6,765,013	07/20/2004	Pfahl et al.			
	A2	US-6,515,003	02/04/2003	Pfahl et al.			
	A3	US-6,262,044	07/17/2001	Møller et al.			
	A4	US-6,127,415	10/03/2000	Pfahl et al.			
	A5	US-5,780,676	07/14/1998	Boehm et al.			
	A6	US-5,691,376	11/25/1997	Cagiano et al.		"	
	A7	US-5,650,444	07/22/1997	Cagiano et al.			
	A8	US-5,523,314	06/04/1996	Bue-Valleskey et al.			
···	A9	US-5,512,689	04/30/1996	Quallich		<del>**                                 </del>	
	A10	US-5,330,998	07/19/1994	Clark et al.			
	A11	US-5,223,522	07/29/1993	Clark et al.			
	A12	US-4,971,996	12/20/1990	Shiraishi et al.			
	A13	US-4,931,279	06/05/1990	Bawa et al.			
	A14	US-4,788,063	11/29/1988	Fisher et al.			
	A15	US-4,713,244	12/15/1987	Bawa et al.			
	A16	US-4,668,506	05/26/1987	Bawa			
	A17	US-4,383,529	05/17/1983	Webster			
	A18	US-4,140,122	02/20/1979	Kühl et al.			
	A19	US-4,051,842	10/04/1977	Hazel et al.			
	A20	US 2004/0097566 A1	05/20/2004	Pfahl et al.			
	A21	US 2004/0034004 A1	02/19/2004	Pfahl et al.			
	A22	US 2003/0216432 A1	11/20/2003	Pfahl et al.			
	A23	US 2003/0153606 A1	08/14/2003	Pfahl et al.			
	A24	US 2003/0144329 A1	07/31/2003	Pfahl <i>et al</i> .			
	A25	US 2003/0105333 A1	06/05/2003	Pfahl <i>et al</i> .			
	A26	US 2003/0083357 A1	05/01/2003	Pfahl et al.			

			REIGN PATE	NT DOCUMENTS	Tananal	
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Transl Yes	ation No
	A27	WO 02/072543	09/19/2002	Pfahl et al. (PCT)		
·	A28	WO 02/072009	09/19/2002	Pfahl et al. (PCT)		
	A29	WO 02/071827	09/19/2002	Gardinier et al. (PCT)		
	A30	WO 01/036402	05/25/2001	Yoneda et al. (PCT including English Abstract, see English translation of EP 1 142 885 related application listed below)		
	A31	WO 01/16123	03/08/2001	Pfahl et al. (PCT).		
	A32	WO 01/16122	03/08/2001	Pfahl et al. (PCT)		

	Sheet 2 of 0				
Complete if Known					
Application Number	10/827,111				
Filing Date	04/19/2004				
First Named Inventor	TACHDJIAN et al.				
Group Art Unit	1614				
Examiner Name	Unassigned				

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document Country Code-Number-Kind Code	Date	Name		lation
Initials	No.	WO 00/66167	11/09/2000	Grubb et al. (PCT)	Yes	No
	A34	WO 00/32598	06/08/2000	Wang et al. (PCT)		1
	A35	WO 00/18748	04/06/2000	Esswein et al. (PCT)		
	A36	WO 00/10573	03/02/2000	Bailey et al. (PCT)		-
	A37	WO 99/58127	11/18/1999	Neogi et al. (PCT)		-
	A38	WO 99/24415	05/20/1999	Kagechika et al. (PCT Cover Sheet including English abstract. See also related Application EP 1 048 659 in English)	,	
-	A39	WO 99/09965	03/04/1999	Odaka et al. (PCT)		
	A40	WO 97/27191	07/31/1997	Vyas et al. (PCT)		
	A41	WO 97/03682	02/06/1997	Fontana (PCT)	-	
	A42	WO 97/00249	01/03/1997	Sohda et al. (PCT)		
	A43	WO 94/12880	06/09/1994	Pfahl et al. (PCT)		
	A44	WO 93/21146	10/28/1993	Boehm et al. (PCT)		
	A45	EP 1 142 885	10/10/2001	Yoneda <i>et al.</i> (EPO) (English application related to WO 01/136402 referenced above)		
	A46	EP 1 048 659	11/02/2000	Kagechika et al. (EPO)		
	A47	EP 0 343 643	11/29/1989	Cetenko et al. (EPO)		
	A48	EP 0 304 493	03/01/1989	Shiraishi et al. (EPO)		
	A49	EP 0 212 617	03/04/1987	Shimada et al. (EPO)	-	
	A50	JP 55 038359	03/17/1980	Tsunekazu et al. (abstract) (Japan)	-	

	NON PATENT LITERATURE DOCUMENT					
Examiner   Cite No.   Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)						
	A51	Alley et al., "Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay," Cancer Re., 48:589-601 (1988)				
	A52	Amin et al., 'Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis," Nitric pin. Rheumatol, 11(3):202-209 (1999)				
	A53	Aranyos et al., "Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers," J. Am. Chem. Soc., 121:4369-4378 (1999)				
		Baraldi et al., "Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children," Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999)				
	A55	Barclay et al., "ortho-Diquaternary aromatic compounds. III. Synthesis and reactions of polyalkyltetralones and derivatives," Canadian Journal of Chemistry, 48(17):2763-2775 (1970)				
	A56	Beilstein Registry No. 29-30, 1975, Compound Registry No 1120438				
A57 Beilstein Registry No. 52, 1978, Compound Registry No 4939128		Beilstein Registry No. 52, 1978, Compound Registry No 4939128				
A58 Black, "Simple Synthesis of 1-Azaadamantan-4-one," Synthesis, 829-830 (1981)		Black, "Simple Synthesis of 1-Azaadamantan-4-one," Synthesis, 829-830 (1981)				
Blondet et al., "Convenient Synthesis of 6-Methyl, 8-Methyl and 6,8-Dimethyl Derivatives of 5-Hydroxy-Tetrahydro-2-Quinolinone," Organic Preparation and Procedures Int., 25(2):223-228 (1993)						

Complete if Known						
Application Number	10/827,111					
Filing Date	04/19/2004					
First Named Inventor	entor TACHDJIAN et al.					
Group Art Unit	1614					
Examiner Name	Unassigned					
	Application Number Filing Date First Named Inventor Group Art Unit					

	NON PATENT LITERATURE DOCUMENT						
Examiner Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	A60	Bradisher et al., "Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid," J. Org. Chem., 15(2) 374-376 (1950)					
	A61	Bredt et al., "Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme," Proc. Natl. Acad. Sci., 87:682-685 (1990)					
	A62	Brennan et al., "Inhibitory Effect of TNF Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," Lancet, 2:244-247 (1989)					
	A63	Cacchi et al., "Palladium-Catalyzed Triethylammonium Formate Reduction of Aryl Triflates. A Selective Method for the deoxygenation of phenols," <i>Tetrahedron Letters</i> , 27(45):5541-5544 (1986)					
	A64	Cantello et al., "A Versatile Route to 2-Arylmethyl-1,2-oxadiazolidine-3,5-diones via Regiospecific Alkyl-ation of 1,2,4-Oxadiazolidine-3,5-dione," Synlett, 263-264 (1997)					
7 2	A65	Cantello et al., "The Synthesis of BRL 49653 – A Novel and Potent Antihyperglycaemic Agent," Bioorganic & Medicinal Chemistry Letters, 4:1181-1184 (1994)					
	A66	Chan et al., "New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate," Tetrahedron Letters, 39:2933-2936 (1998)					
	A67	Chang et al., "The Upjohn Colony of Kkay Mice: A Model for Obese Type II Diabetes," Elsevier Science Publishers B.V., Biomedical Division, Diabetes, pp. 466-470 (1986)					
	A68	Charpentier et al., "Synthesis, Structure – Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes," J. Med. Chem., 38:4993-5006 (1995)					
	A69	Choi et al., "Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention," Gut, 35:950-954 (1994)					
	A70	Cobb et al., "N-(2-Benzoylphenyl)-L-tyrosine PPARy Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent," J. Med. Chem., 41:5055-5069 (1998)					
	A71	Coleman "Diabetes-Obesity Syndromes in Mice," Diabetes, 31(1):1-6 (April 1982)					
	A72	Darses et al., "Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryland Alkenylboronic Acids," Bull. Soc. Chem. Fr., 133:1095-1102 (1996)					
	A73	Dawson et al., "Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity," J. Med. Chemistry, 38:3368-3383 (1995)					
	A74	Dawson et al., "The Synthetic Chemistry of Retinoids," Biology, Chemistry, and Medicine, 2 <sup>nd</sup> Edition, Raven Press, Ltd., New York (1994)					
	A75	Ebisawa et al., "Novel Thiazolidinedione Derivatives with Retinoid Synergistic Activity," Biol. Pharma. Bull., 21(5):547-549 (1998)					
	A76	Evans et al., "Synthesis of Diaryl Ethers through the Copper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine," Tetrahedron Letters, 39:2937-2940 (1998)					
	A77	Farahat et al., "Cytokine Epression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis," Ann. Rheum. Dis., 52: 870-875 (1993)					
	A78	Faul et al., "Synthesis of Novel Retinoid X Receptor-Selective Retinoids," J. Org. Chem., 66:5772-5782 (2001)					
	A79	Ferrell, "Tripping the Switch Fantastic: How A Protein Kinase Cascade Can Convert Graded Inputs into Switch-Like Outputs," TIBS, 21:460-466 (1996)					
	A80	Firooznia et al., "Enantioselective Synthesis of 4-Substituted Phenylalanines By Cross-Coupling Reactions," Tetrahedron Letters, 40:213-216 (1999)					
	A81	Förstermann et al., "Induced RAW 264.7 Macrophages Express Soluble and Particulate Nitric Oxide Synthase: Inhibition By Transforming Growth Factor," Eur. J. Pharm., 225:161-165 (1992)					
	A82	Fukuto et al., "Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition," Annu. Rev. Pharmacol. Toxicol. 35:165-194 (1995)					

	Sneet 4 of 6				
Complete if Known					
Application Number	10/827,111				
Filing Date	04/19/2004				
First Named Inventor	TACHDJIAN et al.				
Group Art Unit	1614				
Examiner Name	Unassigned				

	<u></u>	NON PATENT LITERATURE DOCUMENT
Examiner Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A83	Gahtan et al., "Inflammatory Pathogenesis in Alzheimer's Disease: Biological Mechanisms and Cognitive
	<u> </u>	Sequeli," Neurosci: Biobehav, 23:615-633 (1999)  Glauser et al., "Pathogenesis and Potential Strategies for Prevention and Treatment of Septic Shock: An Update,"
	A84	Clin. Infect Dis. 18 (Suppl. 2):S205-216 (1994)
	A85	Gown, et al., "Human Atherosclerosis - II. Immunocytochemical Analysis of the Cellular Composition of Human
	7103	Atherosclerotic Lesions," Am. J. Pathol., 125(1):191-207 (1986)
	A86	Gray et al., "Practical Methylation of Aryl Halides by Suzuki-Miyaura Coupling," Tetrahedron Letters, 41:6237-6240 (2000)
. ,	A87	Haddach et al., "A New Method for the Synthesis of Ketones: The Palladium-Catalyzed Cross-Coupling of Acid Chlorides with Arylboronic Acids," <i>Tetrahedron Letters</i> , 40:3109-3112 (1999)
	A88	Harris et al., "Localization of a Pioglitazone Response Element in the Adipocyte Fatty Acid-Binding Protein Gene," Mol. Pharmacol., 45:439-445 (1994)
	A89	Hudlicky, "Oxidations in Organic Chemistry," ACS Monograph, 186:114-127 (1990)
	A90	Hudlicky, "Oxidations in Organic Chemistry," ACS Monograph, 186:133-149 (1990)
	A91	Indolese, "Suzuki-Type Coupling of Chloroarenes with Arylboronic Acids Catalysed by Nickel Complexes,"  Tetrahedron Letters, 38:3513-3516 (1997)
	A92	Ishiyama et al., "Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters," J. Org. Chem., 60:7508-7510 (1995)
	A93	Ishiyama et al., "Palladium-Catalyzed Carbonylative Cross-Coupling Reaction of Arylboronic Acids with Aryl Electrophiles: Synthesis of Biaryl Ketones," J. Org. Chem., 63:4726-4731 (1998)
	A94	Ishiyama et al. "Synthesis of Arylboronates via the Palladium(0)-Catalyzed Cross-Coupling Reaction of Tetra(alkoxo)diborons with Aryl Triflates," Tetrahedron Letters, 38:3447-3450 (1997)
	A95	Ishiyama et al. "Synthesis of Unsymmetrical Biaryl Ketones via Palladium-Catalyzed Carbonylative Cross-Coupling Reaction of Arylboronic Acids with Iodoarenes," <i>Tetrahedron Letters</i> , 34:7595-7598 (1993)
	A96	Iwatsuka et al., "General Survey of Diabetic Features of Yellow KK Mice," Endocrinol. Japon. 17:23-35 (1970)
	A97	Jung et al., "New Efficient Method for the Total Synthesis of (S,S)-Isodityrosine from Natural Amino Acids," J. Org. Chem., 64:2976-2977 (1999)
	A98	Kamidawa et al., "Palladium-Catalyzed Amination of Aryl Bromides Utilizing Arene-Chromium Complexes as Ligands," J. Org. Chem., 63:8407-8410 (1998)
	A99	Kawai et al., "Enhancement of Rat Urinary Bladder Tumorigenesis by Lipopolysaccharide-induced inflammation," Cancer Res., 53:5172-5175 (1993)
	A100	Kriegler et al., "A Novel Form of TNF/Cachectin is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF," Cell, 53:45-53 (1988)
	A101	Kyriakis et al., "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation," J. Biol Chem., 271:24313-24316 (1996)
	A102	Littke et al., "A Convenient and General Method for Pd-Catalyzed Suzuki Cross-Couplings of Aryl Chlorides and Arylboronic Acids," Angew. Chem. Int. Ed., 37:3387-3388 (1998)
	A103	Louie et al., "Palladium-Catalyzed Amination of Aryl Triflates and Importance of Triflate Addition Rate," J. Org. Chem., 62:1268-1273 (1997)
	A104	Manickam et al., "New Parts for a Construction Set of Bifunctional Oligo(het)arylene Building Blocks for Modular Chemistry," Synthesis, 3:442-446 (2000)
	A105	McCann et al., "The Nitric Oxide Hypothesis of Aging," Exp. Gerontol, 33(7-8):813-826 (1998)
	A106	McCann, "The Nitric Oxide Hypothesis of Brain Aging," Exp. Gerontol, 32:431-440 (1997)
	A107	Miyaura et al., "Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds," Chem. Rev., 95:2457-2483 (1995)

	Sheet 3 of 0
Com	plete if Known
Application Number	10/827,111
Filing Date	04/19/2004
First Named Inventor	TACHDJIAN et al.
Group Art Unit	1614
Examiner Name	Unassigned

NON PATENT LITERATURE DOCUMENT  Examiner				
Examiner Initials	Cite No.	Non-Patent Citations (include Author, Tide, Publisher, Relevant Pages, Date and Place of Publication)		
	A108	Molina et al., "The Role of Nitric Oxide in Neurodegeneration - Potential for Pharmacological Intervention," Drugs & Aging, 12(4):251-259 (1998)		
	A109	Moroz et al., "The Ullmann Ether Condensation," Russ. Chem. Rev., 43:679-689 (1974)		
	A110	Oliff, "The Role of Tumor Necrosis Factor (Cachectin) in Cachexia," Cell, 54:141-142 (1988)		
	A111	Oram, "Molecular Basic of Cholesterol Homeostasis: Lessons from Tangier Disease and ABCA1," Trends in Molecular Medicines, 8(4):168-173 (2002)		
	A112	Paradisi, "Arene Substitution via Nucleophilic Addition to Electron Deficient Arenes," Comprehensive Organic Synthesis, 4:423-450 (1991)		
	A113	Petrov et al., "The Arbuzov Rearrangement with Participation of Halogenoacetylenes as a Method of Synthesis of Ethynylphosphonates and other Organo-phosphorus Compounds," Russ. Chem. Rev., 52:1030-1035 (1983)		
	A114	Pohlman et al., "An Endothelial Cell Surface Factor(s) Induced in Vitro By Lipopolysaccharide, Interleukin 1, and Tumor Necrosis Factor- Increases Neutrophil Adherence By A CDw18-Dependent Mechanism," J. Immunol, 136:4548-4553 (1986)		
	A115	Pollock et al., "Purification and Characterization of Particulate Endothelium-derived Relaxing Factor Synthase from Cultured and Native Bovine Aortic Endothelial Cells," Proc. Nat. Acad. Sci., 88:10480-10484 (1991)		
	A116	Pujol-Borrell et al., "HLA Class II Induction In Human Islet Cells By Interferon- Plus Tumour Necrosis Factor or Lymphotoxin," Nature, 326:304-306 (1987)		
	A117	Rosin et al., "Inflammation, Chromosomal Instability, and Cancer: The Schistosomiasis Model" Cancer Res., 54 (7 Suppl):1929s-1933s (1994)		
	A118	Ross, "Atherosclerosis - An Inflammatory Disease," New England Journal of Medicine, 340(2):115-126 (January 1999)		
	A119	Rust et al. "Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1," Nature Genetics, 22:352-355 (August 1999)		
	A120	Sanders, "Asthma, Viruses, and Nitric Oxide," Proc. Soc. Exp. Biol. Med., 220(3):123-132 (1999)		
	A121	Schandendorf et al., "Retinoic Acid Receptor-γ Selective Retinoids Exert Antiproliferative Effects on Human Melanoma Cell Growth In Vitro," International Journal of Oncology, 5:1325-1331 (1994)		
	A122	Serfaty-Lacrosniere et al., "Homozygous Tangier disease and cardiovascular disease," Atherosclerosis, 107:85-98 (1994)		
	A123	Shao et al., "p53 Independent G <sub>0</sub> /G <sub>1</sub> Arrest and Apoptosis Induced by a Novel Retinoid in Human Breast Cancer Cells," Oncogene, 11:493-504 (1995)		
	A124	Smith et al., "The Active Form of Tumor Necrosis Factor Is A Trimer," J. Biol. Chem., 262:6951-6954 (1987)		
	A125	Sparrow et al., "A Potent Synthetic LXR Agonist is More Effective than Cholesterol Loading at Inducing ABCA1 mRNA and Stimulating Cholesterol Efflux," Journal of Biological Chemistry, 277(12):10021-10027 (2002)		
	A126	Spruce et al.,"Heteroarotinoids. Synthesis, Characterization, and Biological Activity in Terms of an Assessment of these Systems to Inhibit the Induction of Ornithine Decarboxylase Activity and to Induce Terminal Differentiation of HL-60 Cells," J. Med. Chem., 30:1474-1482 (1987)		
	A127	Stanforth, "Catalytic Cross-Coupling Reactions in Biaryl Synthesis," Tetrahedron, 54:263-303 (1998)		
<del>-</del>	A128	Stirling et al., "Increase In Exhaled Nitric Oxide Levels in patients With Difficult Asthma and Correlation With Symptoms and Disease Severity Despite Treatment With Oral and Inhaled Corticosteroids," <i>Thorax</i> , 53(12):1030-1034 (1998)		
	A129	Strieter et al., "Endothelial Cell Gene Expression of a Neutrophil Chemotactic Factor by TNF-, LPS, and IL-1," Science, 243:1467-1469 (1989)		
	A130	Suzuki, "New Synthetic Transformations Via Organoboron Compounds," Pure & Applied Chem., 66:213-222 (1994)		

(Use as many sheets as necessary)

Con	mplete if Known
Application Number	10/827,111
Filing Date	04/19/2004
First Named Inventor	TACHDJIAN et al.
Group Art Unit	1614
Examiner Name	Unassigned

		NON PATENT LITERATURE DOCUMENT	
Examiner Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)	
	A131	Teboul et al., "Thiazolidinediones and Fatty Acids Convert Myogenic Cells Into Adipose-like Cells," J. Biol. Chem., 270:28183-28187 (1995)	
	A132	Thompson et al., "Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea," Carginogenesis, 13(9):1535-1539 (1992)	
	A133	Thorns et al., "nNOS Expressing Neurons in the Entorhinal Cortex and Hippocampus Are Affected in Patients With Alzheimer's Disease," Exp. Neurol, 150:14-20 (1998)	
	A134	Tietze et al., "The Knoevenagel Reaction," Comprehensive Organic Synthesis, 2:341-394 (1991)	
	A135	Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," Nature, 330:662-664 (1987)	
	A136	Tracey et al., "Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapuetic Target," Ann. Rev. Med., 45:491 503 (1994)	
	A137	Uysal et al. "Protection From Obesity-induced Insulin Resistance in Mice Lacking TNF- Function," Nature, 389:610-614 (1997)	
	A138	Wadsworth, "Synthetic Applications of Phosphoryl-Stabilized Anions," Organic Reactions, 25:73-253 (1977)	
	A139	Walter et al., "The High Density Lipoprotein – and Apolipoprotein A-1-Induced Mobilization of Cellular Cholesterol is Impaired in Fibroblasts from Tangier Disease Subjects," Biochemical and Biophysical Research Communications, 205(1):850-856 (1994)	
	A140	Watanabe et al., "Synthesis of Sterically Hindered Biaryls via the Palladium-Catalyzed Cross-Coupling Reaction of Arylboronic Acids or Their Esters With Haloarenes," Synlett., 207-210 (1992)	
	A141	Weiberth et al., "Copper(I)-Activated Addition of Grignard Reagents to Nitriles. Synthesis of Ketimines, Ketones, and Amines," J. Org. Chem., 52:3901-3904 (1987)	
	A142	Willson et al., "The Structure-Activity Relationship Between Peroxisome Proliferator-Activated Receptor Agonism and the Antihyperglycemic Activity of Thiazolidinediones," J. Med. Chem., 39:665-668 (1996)	
	A143	Wolfe et al., "Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides," J. Org. Chem., 65:1144-1157 (2000)	
· ·	A144	Wolfe et al., "Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides and Triflates," J. Org. Chem., 65:1158-1174 (2000)	
	A145	Xiong et al.,"Human D-Type Cyclin," Cell, 65:691-699 (1991)	
	A146	Yun et al., "Neurobiology of Nitric Oxide," Crit. Rev. Neurobiol., 10:291-316 (1996)	
	A147	Zask et al., "Synthesis of 3-Mercapto-2(5H)-Furanones via Reaction of Dilithio-2,4-thiazolidinedione With -Hale Ketones," Tetrahedron Letters, 34 (17):2719-2722 (1993)	
	A148	Zask et al., "Synthesis and Antihyperglycemic Activity of Novel 5-(naphthalenylsufonyl)-2,4-thiazolidinediones," J.Med.Chem., 33:1418-1423 (1990)	
Examiner Signature:		Date Considered:  ference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.